Graves Disease clinical trials

Explore recruiting graves disease clinical trials.

Recruiting graves disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Graves Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thyroid Eye Disease

Germany, Italy, Austria, Hungary, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

Italy, Poland, Greece, Germany, Netherlands, Czechia +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

Italy, Greece, Germany, Hungary, Poland, Czechia +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to test single and multiple doses of MER511 given to adults with Graves’ disease

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An open-label Phase 2 study to investigate the efficacy and safety of rilzabrutinib in adult participants with Graves’ disease

Spain, Italy, Germany, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Graves Disease trials by city

Graves Disease in Toronto Graves Disease in Vancouver Graves Disease in Montreal Graves Disease in Calgary Graves Disease in Edmonton Graves Disease in Ottawa Graves Disease in Winnipeg Graves Disease in Quebec City Graves Disease in Hamilton Graves Disease in Kitchener Graves Disease in London Graves Disease in Halifax Graves Disease in New York Graves Disease in Los Angeles Graves Disease in Chicago Graves Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease